See more : Coastal Financial Corporation (CCB) Income Statement Analysis – Financial Results
Complete financial analysis of Roche Holding AG (RHHBY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Roche Holding AG, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- Rover Metals Corp. (ROVR.V) Income Statement Analysis – Financial Results
- The Tinplate Company of India Limited (TINPLATE.NS) Income Statement Analysis – Financial Results
- Isamu Paint Co., Ltd. (4624.T) Income Statement Analysis – Financial Results
- Scienjoy Holding Corporation (SJOYW) Income Statement Analysis – Financial Results
- Rheinmetall AG (RNMBY) Income Statement Analysis – Financial Results
Roche Holding AG (RHHBY)
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 60.44B | 63.28B | 62.80B | 58.32B | 61.47B | 56.85B | 53.30B | 50.58B | 48.15B | 47.46B | 46.78B | 45.50B | 42.53B | 47.47B | 49.05B | 45.62B | 46.13B | 42.04B | 35.51B | 31.27B | 31.22B | 29.73B | 29.16B | 28.67B | 27.57B | 24.66B |
| Cost of Revenue | 16.36B | 20.40B | 19.65B | 16.18B | 18.35B | 17.27B | 18.18B | 16.18B | 15.46B | 13.38B | 11.95B | 12.18B | 11.94B | 13.29B | 14.62B | 13.66B | 13.74B | 10.62B | 9.30B | 7.18B | 8.32B | 8.43B | 8.34B | 9.16B | 8.87B | 7.90B |
| Gross Profit | 44.08B | 42.88B | 43.15B | 42.15B | 43.12B | 39.58B | 35.12B | 34.40B | 32.69B | 34.08B | 34.83B | 33.32B | 30.59B | 34.18B | 34.44B | 31.96B | 32.39B | 31.43B | 26.21B | 24.09B | 22.91B | 21.29B | 20.82B | 19.51B | 18.69B | 16.76B |
| Gross Profit Ratio | 72.94% | 67.77% | 68.72% | 72.26% | 70.14% | 69.62% | 65.89% | 68.01% | 67.89% | 71.81% | 74.46% | 73.24% | 71.92% | 72.00% | 70.20% | 70.05% | 70.21% | 74.75% | 73.80% | 77.03% | 73.37% | 71.63% | 71.41% | 68.04% | 67.81% | 67.96% |
| Research & Development | 14.20B | 16.02B | 14.80B | 13.01B | 12.77B | 12.09B | 11.29B | 11.53B | 9.58B | 9.90B | 9.27B | 9.55B | 8.33B | 10.03B | 9.87B | 8.85B | 8.39B | 6.59B | 5.71B | 5.09B | 4.77B | 4.26B | 3.89B | 3.95B | 3.78B | 3.41B |
| General & Administrative | 14.88B | 2.89B | 3.33B | 3.04B | 4.12B | 5.26B | 3.43B | 1.72B | 2.73B | 3.84B | 2.65B | 3.05B | 2.34B | 2.87B | 2.18B | 2.33B | 2.45B | 2.54B | 11.91B | 10.41B | 10.30B | 9.83B | 9.67B | 9.99B | 8.99B | 7.83B |
| Selling & Marketing | 0.00 | 9.64B | 9.92B | 9.57B | 10.96B | 10.11B | 9.85B | 9.14B | 8.81B | 8.66B | 8.37B | 8.54B | 8.05B | 9.49B | 9.48B | 9.17B | 9.33B | 10.86B | 9.51B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.88B | 12.53B | 13.25B | 12.61B | 15.08B | 15.37B | 13.27B | 10.86B | 11.54B | 12.50B | 11.02B | 11.59B | 10.39B | 12.36B | 11.65B | 11.50B | 11.78B | 13.40B | 11.91B | 10.41B | 10.30B | 9.83B | 9.67B | 9.99B | 8.99B | 7.83B |
| Other Expenses | -392.00M | -192.00M | -238.00M | -265.00M | -227.00M | -197.00M | -311.00M | -316.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 28.69B | 25.41B | 25.00B | 23.60B | 25.57B | 24.83B | 22.12B | 20.33B | 18.86B | 19.99B | 18.46B | 19.21B | 17.15B | 20.71B | 19.45B | 18.06B | 17.92B | 19.71B | 17.54B | 15.11B | 17.31B | 19.96B | 17.58B | 12.38B | 12.27B | 12.39B |
| Cost & Expenses | 45.05B | 45.81B | 44.65B | 39.78B | 43.92B | 42.10B | 40.30B | 36.51B | 34.32B | 33.37B | 30.40B | 31.39B | 29.09B | 34.01B | 34.06B | 31.72B | 31.67B | 30.33B | 26.84B | 22.29B | 25.63B | 28.39B | 25.92B | 21.54B | 21.15B | 20.29B |
| Interest Income | 183.00M | 67.00M | 342.00M | 16.00M | 99.00M | 30.00M | 30.00M | 22.00M | 24.00M | 34.00M | 27.00M | 32.00M | 73.00M | 51.00M | 179.00M | 698.00M | 1.07B | 788.00M | 423.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 997.00M | 690.00M | 419.00M | 553.00M | 791.00M | 744.00M | 765.00M | 958.00M | 1.11B | 1.18B | 1.33B | 2.00B | 2.01B | 2.55B | 2.44B | 214.00M | 281.00M | 315.00M | 264.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.46B | 3.82B | 4.45B | 4.57B | 4.31B | 3.60B | 3.89B | 3.95B | 3.64B | 2.62B | 2.38B | 2.42B | 2.37B | 2.55B | 2.69B | 2.65B | 2.54B | 2.44B | 1.01B | 1.61B | 1.51B | 1.52B | 1.55B | 2.85B | 2.45B | 2.07B |
| EBITDA | 18.54B | 20.86B | 22.86B | 23.08B | 21.70B | 22.51B | 21.19B | 17.91B | 16.74B | 19.13B | 18.99B | 16.24B | 16.29B | 16.27B | 15.50B | 16.48B | 18.12B | 15.34B | 9.68B | 10.58B | 7.10B | 2.86B | 4.80B | 27.57B | 8.87B | 6.44B |
| EBITDA Ratio | 30.67% | 34.02% | 36.40% | 38.58% | 35.37% | 31.95% | 31.52% | 35.38% | 35.44% | 35.03% | 39.76% | 37.30% | 38.48% | 34.69% | 37.52% | 36.12% | 37.31% | 33.97% | 27.26% | 33.84% | 22.75% | 9.60% | 16.46% | 34.80% | 32.19% | 26.13% |
| Operating Income | 15.40B | 17.48B | 18.16B | 18.54B | 17.55B | 14.77B | 13.00B | 14.07B | 13.82B | 14.09B | 16.38B | 14.13B | 13.45B | 13.49B | 12.28B | 13.92B | 14.47B | 11.73B | 8.67B | 8.98B | 5.59B | 1.34B | 3.25B | 7.13B | 6.42B | 4.37B |
| Operating Income Ratio | 25.47% | 27.62% | 28.91% | 31.79% | 28.55% | 25.98% | 24.40% | 27.82% | 28.71% | 29.69% | 35.01% | 31.04% | 31.63% | 28.41% | 25.03% | 30.52% | 31.36% | 27.90% | 24.41% | 28.71% | 17.91% | 4.49% | 11.13% | 24.87% | 23.29% | 17.72% |
| Total Other Income/Expenses | -1.32B | -1.15B | -757.00M | -578.00M | -934.00M | -621.00M | -755.00M | -1.06B | -1.83B | -1.58B | -1.70B | -1.97B | -1.57B | -2.28B | -2.05B | 237.00M | 836.00M | 857.00M | 133.00M | 506.00M | -711.00M | -4.53B | 1.52B | 2.34B | 1.13B | 1.08B |
| Income Before Tax | 14.08B | 16.33B | 17.40B | 17.97B | 16.61B | 14.15B | 12.25B | 13.01B | 11.99B | 12.52B | 14.68B | 12.32B | 11.89B | 11.21B | 10.23B | 14.16B | 15.30B | 12.59B | 8.97B | 9.49B | 4.88B | -3.19B | 4.76B | 9.47B | 7.56B | 5.45B |
| Income Before Tax Ratio | 23.29% | 25.80% | 27.70% | 30.80% | 27.03% | 24.89% | 22.98% | 25.72% | 24.90% | 26.37% | 31.37% | 27.08% | 27.94% | 23.62% | 20.86% | 31.04% | 33.17% | 29.94% | 25.25% | 30.33% | 15.63% | -10.75% | 16.33% | 33.02% | 27.41% | 22.11% |
| Income Tax Expense | 1.72B | 2.80B | 2.46B | 2.90B | 2.51B | 3.28B | 3.42B | 3.27B | 2.93B | 2.98B | 3.30B | 2.55B | 2.34B | 2.32B | 1.72B | 3.32B | 3.87B | 3.44B | 2.22B | 2.35B | 1.45B | 839.00M | 1.04B | 2.27B | 1.90B | 965.00M |
| Net Income | 11.50B | 12.42B | 13.93B | 14.30B | 13.50B | 10.50B | 8.63B | 9.58B | 8.86B | 9.33B | 11.16B | 9.43B | 9.34B | 8.67B | 7.78B | 8.97B | 9.76B | 7.88B | 5.92B | 6.61B | 3.07B | -4.03B | 3.70B | 8.65B | 5.76B | 4.39B |
| Net Income Ratio | 19.02% | 19.63% | 22.18% | 24.51% | 21.96% | 18.47% | 16.20% | 18.93% | 18.41% | 19.66% | 23.86% | 20.72% | 21.97% | 18.25% | 15.87% | 19.66% | 21.16% | 18.74% | 16.68% | 21.12% | 9.83% | -13.54% | 12.68% | 30.16% | 20.91% | 17.81% |
| EPS | 14.31 | 1.94 | 2.05 | 2.09 | 1.97 | 1.54 | 1.26 | 1.41 | 1.30 | 1.37 | 1.65 | 1.39 | 1.38 | 1.27 | 1.13 | 1.30 | 1.42 | 1.16 | 0.88 | 0.98 | 0.46 | -0.60 | 0.55 | 1.29 | 0.84 | 0.64 |
| EPS Diluted | 14.30 | 1.94 | 2.03 | 2.07 | 1.95 | 1.53 | 1.25 | 1.39 | 1.29 | 1.35 | 1.62 | 1.38 | 1.37 | 1.26 | 1.13 | 1.28 | 1.40 | 1.13 | 0.86 | 0.97 | 0.45 | -0.60 | 0.55 | 1.28 | 0.84 | 0.64 |
| Weighted Avg Shares Out | 803.49M | 6.40B | 6.80B | 6.84B | 6.85B | 6.83B | 6.82B | 6.82B | 6.81B | 6.79B | 6.78B | 6.78B | 6.79B | 6.84B | 6.86B | 6.88B | 6.87B | 6.82B | 6.76B | 6.72B | 6.71B | 6.71B | 6.72B | 6.72B | 6.90B | 6.90B |
| Weighted Avg Shares Out (Dil) | 804.00M | 6.40B | 6.88B | 6.92B | 6.91B | 6.88B | 6.88B | 6.88B | 6.90B | 6.90B | 6.90B | 6.84B | 6.81B | 6.86B | 6.87B | 6.89B | 6.90B | 6.90B | 6.88B | 6.80B | 6.80B | 6.71B | 6.90B | 6.76B | 6.90B | 6.90B |
Europe is a 'soufflé collapsing' from the turmoil in France and Germany: David Roche
David Roche of Quantum Strategy discusses the limited impact to the Euro and French OAT spreads following the recent no-confidence vote that ousted French Prime Minister Michel Barnier. He discusses his broader outlook for Europe and what it would take...
FDA Accepts Roche's Columvi sBLA for Expanded Use in Lymphoma
The FDA accepts RHHBY's sBLA seeking the label expansion of Columvi to include the treatment of second-line R/R DLBCL for review.
FDA accepts supplemental Biologics License Application for Roche's Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
Basel, 5 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for Columvi® (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx)...
FDA Accepts Supplemental Biologics License Application for Genentech's Columvi Combination for People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for Columvi® (glofitamab-gxbm) in combination...
Poseida shares triple on Tuesday, boosted by Roche collaboration
Shares of Poseida Therapeutics Inc (NASDAQ: PSTX) more than tripled this morning after Roche Holding (SWX: ROG) said it will buy the clinical-stage biopharmaceutical company for about $1.5 billion. Roche's offer values each share of Poseida Therapeutics at $9.0 that...
Roche to Acquire CAR-T Cell Therapy Focused Poseida for $1.5B
RHHBY is all set to acquire Poseida Therapeutics, Inc. and ramp up its pipeline with off-the-shelf cell therapies.
Unity Bank's Amanda Roche Honored as a New Leader in Banking by NJ Bankers Association
Prestigious Recognition Celebrates Rising Stars in New Jersey's Banking Industry Prestigious Recognition Celebrates Rising Stars in New Jersey's Banking Industry
Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details
On Tuesday, Roche Holdings AG RHHBY agreed to acquire Poseida Therapeutics, Inc. PSTX for an equity value of approximately $1.5 billion on a fully diluted basis.
Roche records setback in phase III study of two lung cancer drugs
A Roche study into using a combination of tiragolumab and tecentriq to treat a form of lung cancer in a phase III trial did not achieve the desired success, the Swiss pharmaceuticals maker said on Tuesday.
Roche to acquire US-based Poseida Therapeutics
Roche will acquire California-based biopharmafirm Poseida Therapeutics for $9 per share at closing, for a total equity value of $1 billion, the Swiss company said on Tuesday.
Source: https://incomestatements.info
Category: Stock Reports